Revvity, Inc. (NYSE: RVTY) has declared a regular quarterly dividend of $0.07 per share of common stock, signaling its ongoing commitment to shareholder returns. The Board of Directors approved the payout, which will be distributed to all shareholders of record at the close of business on October 23, 2026. This declaration underscores the company's stable financial position and its strategy to provide consistent income to its investor base.

The dividend is payable on November 13, 2026. Shareholders must hold the company's common stock by the record date to be eligible for the payment. The Board of Directors determined that this distribution aligns with the company's current cash flow generation and future capital requirements.

Dividend Details

Company Overview

Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. The company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, and informatics. With approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech sectors, diagnostic labs, academia, and governments in more than 160 countries. The company reported revenue of $2.9 billion in 2025 and is part of the S&P 500 index.

Revvity published its 2026 Impact Report, detailing advancements in its environmental, social, and governance strategy. The report highlights the company's progress in sustainability, including the disclosure of material Scope 3 emissions for the first time. This expansion of reporting transparency accompanies a 1.3% reduction in Scope 1 and 2 greenhouse gas emissions in 2025, contributing to a 16% total reduction from the 2022 baseline.

Environmental Performance

Revvity achieved a 49% non-hazardous diversion rate, surpassing its annual goal of 40%. The company continues to focus on lowering its carbon footprint through operational efficiencies and sustainable practices.

Social and Governance Initiatives

The report outlines advancements in talent retention and workforce development. Voluntary turnover decreased to 7% from 9%, with 24% of open roles filled through internal promotions and transfers. Revvity also launched the Revvity Supports Research (RSR) initiative, providing $180,000 in general research grants to 12 academic institutions.

Key Metrics

With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia, and governments in more than 160 countries.